Re:Pair Genomics, a Toronto-based biotechnology company, is working to accelerate the development of gene therapies for rare diseases using artificial intelligence. Founded by researchers from the University of Toronto and led by CEO Shiron Lee, the company has developed a machine learning algorithm that can design customized genetic components in as little as a day, significantly reducing a process that traditionally takes months of laboratory screening.
In a recent TELUS Business feature, Lee discusses the challenges of translating academic research into real-world healthcare innovation. She highlights the importance of generating scientific evidence, securing funding, and navigating the resource-intensive nature of biotech entrepreneurship. The article also explores how Re:Pair Genomics uses AI to streamline operations, from grant applications to business development, allowing its lean team to focus on advancing its technology.
The story underscores the growing role of AI in both scientific discovery and business operations, demonstrating how emerging technologies can help innovative startups move promising healthcare solutions from the lab to the marketplace. Through its work, Re:Pair Genomics aims to improve the precision and safety of future gene therapies while helping address unmet needs in rare disease treatment.
Read the full story on the TELUS website to learn more about Re:Pair Genomics, Shiron Lee's entrepreneurial journey, and how AI is helping advance the future of gene therapy.
